Drug intelligence / Profile preview

IMB1005

Development stage: Preclinical
Lead developer: IMIDomics
Modality: Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IMB1005 is a drug candidate initially developed by Imidomics, Inc. It is currently in preclinical development, primarily targeting digestive system disorders, with a specific focus on ulcerative colitis. The drug is associated with technology platforms involving monoclonal antibodies, bispecific antibodies, and protein drugs, suggesting it is a biologic agent designed to modulate immune responses.

Beyond the preview

Go deeper on IMB1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB1005.

Explore the full profile